Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis
Chiang CS., Kassianos AJ., Healy HG., Ng MSY.
Narrative Review on Chronic Kidney Disease, Chronic Inflammation, published in Clin Transl Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Clin Transl Med (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42011979
- PMCID
- PMC13097387
- DOI
- 10.1002/ctm2.70587
Abstract (original English)
Kidney fibrosis is mechanistically characterised by tissue injury followed by development of a fibrogenic niche. The fibrogenic niche involves chronic inflammation, vascular rarefaction, glomerulosclerosis, tubular atrophy, interstitial accumulation of extracellular matrix which replaces functional kidney parenchyma-culminating in reduced kidney function. Extracellular vesicles are bilipid membrane-encased nanoparticles that play critical roles as cell-to-cell messengers and waste management mechanisms. Extracellular vesciels communication has been demonstrated within the glomerulus, within the tubular compartment and, between tubular and glomerular compartments. Diverse extracellular vesicle cargoes interact with key pathways regulating cell facte and inflammation to mediate kidney fibrosis. Extracellular vesicles cargos can be leveraged as biomarkers to develop minimally invasive tests for kidney fibrosis and pinpoint active pathobiological processes to guide personalised mechanism-driven care. Mesechymal cell-derived extracellular vesicles, extracellular vesicles from bioengineered cells, post-modified extracellular vesicles and suppression of extracellular vesicle uptake have demonstrated promise in preclinical studies for preventing kidney fibrosis. Roadblocks to clinical implementation of extracellular vesicles as biomarkers include lack of standardised collection, measur
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations